Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms —Reply
In Reply We appreciate the interest in and valuable thoughts of Zhu et al on our international Delphi consensus on the treatment of adult patients with drug reaction with eosinophilia and systemic symptoms (DRESS). We thank them for their reflections on the role of human herpesvirus 6 (HHV-6) reactivation in DRESS. The authors address 3 important points. (Source: JAMA Dermatology)
Source: JAMA Dermatology - May 1, 2024 Category: Dermatology Source Type: research
Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms
To the Editor We read the article by Br üggen et al that outlined international consensus guidelines for the management of drug rash with eosinophilia and systemic symptoms (DRESS) with great interest. These were the first guidelines published that formally recommended routine screening for human herpesviruses: cytomegalovirus (CMV), Eps tein-Barr virus, and human herpesvirus 6A (HHV-6A) and 6B (HHV-6B). Consideration of antiviral medication (ie, valganciclovir or ganciclovir) for high CMV viral load is also an unprecedented formal recommendation. We fully support these recommendations, as viral reactivation has been asso...
Source: JAMA Dermatology - May 1, 2024 Category: Dermatology Source Type: research
Methotrexate Use and Risk of Interstitial Lung Disease in Dermatomyositis
This cohort study examines the association between methotrexate use and interstitial lung disease in patients with dermatomyositis. (Source: JAMA Dermatology)
Source: JAMA Dermatology - May 1, 2024 Category: Dermatology Source Type: research
Definition and Diagnostic Criteria for Generalized Pustular Psoriasis
This consensus statement develops an international definition and diagnostic criteria for generalized pustular psoriasis using the modified Delphi model. (Source: JAMA Dermatology)
Source: JAMA Dermatology - May 1, 2024 Category: Dermatology Source Type: research
Retiform Ulceration and Bullae on the Bilateral Thighs
A man with a history of polysubstance use presents with new bullae on his bilateral lower extremities. What is your diagnosis? (Source: JAMA Dermatology)
Source: JAMA Dermatology - May 1, 2024 Category: Dermatology Source Type: research
Rethinking the Approach to Nail Disorders
This Viewpoint discusses the need for a broader approach to nail pathology, in which infectious, inflammatory, systemic, and structural factors are considered. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
This cross-sectional study examines the stigmatization of children and adolescents associated with the visibility and severity of chronic skin disorders. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
ALK -Positive Histiocytosis —A Distinct Histiocytic Entity Deserving Recognition—Reply
In Reply We read the Letter to the Editor by Kemps et al with interest. We believe that these cases belong to the spectrum of juvenile xanthogranuloma (JXG). Conventionally, JXG is divided into 3 clinical stages during the disease process (the early developed, xanthomatous, and regression stages) and 3 histopathological changes are observed accordingly (the early, classic, and transitional stages). In our previous study, approximately 34.8% of systemic JXG exhibited ALK-positive immunostaining and ALK translocation verified via ALK fluorescence in situ hybridization assays. Furthermore, 17.4% were BRAFV600E- variants. This...
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
ALK -Positive Histiocytosis —A Distinct Histiocytic Entity Deserving Recognition
To the Editor It is with great interest that we read the recent article by Xu et al that described 2 infants with systemic histiocytic neoplasms harboring ALK translocations who were successfully treated with the ALK inhibitor alectinib. To our surprise, the authors classified the disease as systemic juvenile xanthogranuloma (JXG) without any mention of ALK-positive histiocytosis and stated that the treatment method had not been previously reported. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Trichomegaly Due to Panitumumab
This case report describes an adult male patient with a severe acneiform eruption on his chest and back. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Rosacea Core Domain Set
This consensus statement uses the Delphi process to develop a core domain set for rosacea clinical trials and practice. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Laser and Light-Based Therapies for Hirsutism Management in Women With Polycystic Ovarian Syndrome
This Systematic Review synthesizes the existing literature regarding the effectiveness of laser and light hair reduction therapies, either as stand-alone treatments or in combination with systemic agents, in treating hirsutism for women with polycystic ovary syndrome. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Efficacy and Safety of Erenumab for Erythema and Flushing in Rosacea
This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti –calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Weekly Laser Treatments for Port-Wine Birthmarks in Infants
This case series examines the improvement in port-wine birthmark clearance from before to after once-weekly pulsed dye laser therapy in patients younger than 6 months. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Treatment of Keratosis Lichenoides Chronica With Upadacitinib
This case report describes a 30-year-old man presenting with 1-year history of nonitchy red papules and patches who was subsequently treated with upadacitinib. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
